Nifty
Sensex
:
:
11095.25
37687.91
203.65 (1.87%)
748.31 (2.03%)

Pharmaceuticals & Drugs - Global

Rating :
73/99  (View)

BSE: 524804 | NSE: AUROPHARMA

864.10
-2.70 (-0.31%)
04-Aug-2020 | 3:59PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  868.50
  •  874.65
  •  850.50
  •  866.80
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  2668420
  •  23057.82
  •  887.10
  •  288.85

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 50,838.96
  • 17.96
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 55,848.54
  • 0.29%
  • 3.02

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 52.01%
  • 1.40%
  • 8.29%
  • FII
  • DII
  • Others
  • 22.63%
  • 12.48%
  • 3.19%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.53
  • 10.05
  • 9.48

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 16.99
  • 9.04
  • 2.85

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 15.46
  • 8.43
  • 0.94

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 17.77
  • 17.53
  • 15.47

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.16
  • 4.16
  • 2.96

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 12.56
  • 12.13
  • 10.48

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 20
Mar 19
Var%
Dec 19
Dec 18
Var%
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Net Sales
6,158
5,292
16%
5,895
5,270
12%
5,600
4,751
18%
5,445
4,250
28%
Expenses
4,842
4,235
14%
4,687
4,183
12%
4,460
3,765
18%
4,298
3,539
21%
EBITDA
1,316
1,057
24%
1,208
1,086
11%
1,140
986
16%
1,146
711
61%
EBIDTM
21%
20%
20%
21%
20%
21%
21%
17%
Other Income
33
32
1%
31
64
-52%
21
26
-21%
16
44
-64%
Interest
32
50
-36%
37
48
-22%
41
35
16%
50
30
69%
Depreciation
232
187
25%
250
163
53%
243
164
49%
241
155
56%
PBT
1,097
817
34%
939
914
3%
864
787
10%
859
571
50%
Tax
229
231
-1%
233
205
14%
224
175
28%
228
116
97%
PAT
868
586
48%
706
710
-1%
639
611
5%
631
455
39%
PATM
14%
11%
12%
13%
11%
13%
12%
11%
EPS
14.82
10.00
48%
12.05
12.11
0%
10.91
10.43
5%
10.77
7.77
39%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
23,098
19,564
16,463
14,910
13,795
12,121
8,100
5,855
4,627
4,381
3,575
Net Sales Growth
18%
19%
10%
8%
14%
50%
38%
27%
6%
23%
 
Cost Of Goods Sold
9,735
7,886
6,086
5,911
5,612
5,100
3,276
2,730
2,304
1,964
1,575
Gross Profit
13,363
11,677
10,377
8,999
8,182
7,021
4,824
3,125
2,323
2,418
2,001
GP Margin
58%
60%
63%
60%
59%
58%
60%
53%
50%
55%
56%
Total Expenditure
18,288
15,612
12,691
11,475
10,607
9,557
5,966
4,994
4,066
3,418
2,752
Power & Fuel Cost
-
557
471
437
419
360
350
325
232
208
195
% Of Sales
-
3%
3%
3%
3%
3%
4%
6%
5%
5%
5%
Employee Cost
-
2,585
2,131
1,768
1,543
1,302
802
663
536
425
324
% Of Sales
-
13%
13%
12%
11%
11%
10%
11%
12%
10%
9%
Manufacturing Exp.
-
2,038
1,611
1,310
1,256
1,023
772
623
543
512
349
% Of Sales
-
10%
10%
9%
9%
8%
10%
11%
12%
12%
10%
General & Admin Exp.
-
1,007
1,068
997
686
666
283
198
131
120
117
% Of Sales
-
5%
6%
7%
5%
6%
4%
3%
3%
3%
3%
Selling & Distn. Exp.
-
1,123
1,026
848
902
879
360
306
208
142
144
% Of Sales
-
6%
6%
6%
7%
7%
4%
5%
4%
3%
4%
Miscellaneous Exp.
-
416
299
204
188
227
123
149
112
48
144
% Of Sales
-
2%
2%
1%
1%
2%
2%
3%
2%
1%
1%
EBITDA
4,811
3,952
3,772
3,434
3,188
2,564
2,134
861
561
963
823
EBITDA Margin
21%
20%
23%
23%
23%
21%
26%
15%
12%
22%
23%
Other Income
100
155
102
116
204
97
22
29
25
71
151
Interest
160
263
78
67
257
160
310
267
277
65
73
Depreciation
967
668
558
428
392
333
313
249
201
172
149
PBT
3,758
3,177
3,238
3,056
2,743
2,168
1,533
374
108
799
752
Tax
914
727
818
760
721
597
363
83
-89
225
191
Tax Rate
24%
24%
25%
25%
26%
28%
24%
22%
42%
29%
25%
PAT
2,845
2,362
2,420
2,297
2,024
1,576
1,173
294
-124
563
561
PAT before Minority Interest
2,846
2,362
2,420
2,296
2,022
1,571
1,169
291
-124
563
561
Minority Interest
1
0
0
0
2
5
4
2
1
0
0
PAT Margin
12%
12%
15%
15%
15%
13%
14%
5%
-3%
13%
16%
PAT Growth
20%
-2%
5%
13%
28%
34%
299%
338%
-122%
0%
 
EPS
48.55
40.31
41.30
39.20
34.54
26.89
20.02
5.02
-2.11
9.62
9.58

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
13,891
11,680
9,372
7,287
5,156
3,750
2,606
2,340
2,445
1,829
Share Capital
59
59
59
59
29
29
29
29
29
28
Total Reserves
13,832
11,622
9,313
7,228
5,127
3,721
2,577
2,311
2,416
1,801
Non-Current Liabilities
336
594
102
584
1,592
1,494
1,225
967
645
2,246
Secured Loans
180
451
178
380
774
1,101
1,084
862
450
864
Unsecured Loans
0
0
4
363
588
178
64
103
74
1,291
Long Term Provisions
47
56
39
23
24
9
9
4
3
0
Current Liabilities
12,043
8,666
6,606
7,840
6,136
4,220
3,431
2,915
2,768
708
Trade Payables
2,677
2,373
2,155
2,457
2,051
1,351
964
660
776
604
Other Current Liabilities
2,545
1,967
1,287
1,578
1,365
388
151
580
699
68
Short Term Borrowings
6,573
4,031
2,903
3,673
2,502
2,355
2,236
1,608
1,235
0
Short Term Provisions
247
294
261
133
218
127
80
66
58
35
Total Liabilities
26,271
20,942
16,082
15,714
12,910
9,490
7,273
6,232
5,868
4,787
Net Block
8,475
6,521
4,834
4,180
3,706
2,722
2,639
2,195
1,739
1,711
Gross Block
10,498
7,895
5,635
4,570
5,446
4,183
3,763
3,086
2,438
2,408
Accumulated Depreciation
2,023
1,374
802
390
1,740
1,461
1,125
892
699
697
Non Current Assets
10,907
8,764
6,875
5,420
4,611
3,859
3,136
2,968
2,547
2,280
Capital Work in Progress
1,668
1,583
1,458
848
370
257
168
516
583
570
Non Current Investment
360
312
246
123
0
20
22
20
38
0
Long Term Loans & Adv.
364
262
256
237
455
789
238
108
111
0
Other Non Current Assets
39
87
81
32
30
18
19
0
1
0
Current Assets
15,365
12,178
9,206
10,294
8,299
5,631
4,137
3,264
3,321
2,507
Current Investments
0
0
0
0
20
0
0
19
0
1
Inventories
7,246
5,858
4,331
4,056
3,611
2,368
1,924
1,546
1,455
1,102
Sundry Debtors
3,414
3,080
2,765
4,607
3,539
2,637
1,597
1,240
1,231
956
Cash & Bank
1,957
1,262
513
800
469
179
208
71
187
73
Other Current Assets
2,748
1,223
1,085
464
660
448
408
389
448
375
Short Term Loans & Adv.
828
754
512
367
388
237
208
217
359
281
Net Current Assets
3,322
3,512
2,601
2,454
2,162
1,411
706
349
553
1,799
Total Assets
26,271
20,942
16,082
15,714
12,910
9,490
7,273
6,232
5,868
4,787

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
1,622
1,955
3,279
1,420
1,237
646
275
326
335
425
PBT
3,091
3,241
3,061
2,744
2,168
1,533
374
108
799
752
Adjustment
811
535
409
488
406
515
442
387
198
100
Changes in Working Capital
-1,510
-1,123
583
-1,079
-842
-1,057
-422
-128
-469
-274
Cash after chg. in Working capital
2,392
2,653
4,052
2,152
1,732
990
394
367
527
578
Interest Paid
0
0
0
0
0
0
0
0
0
0
Tax Paid
-770
-699
-774
-733
-496
-344
-119
-41
-192
-153
Other Direct Exp. Paid
0
0
0
0
0
0
0
0
0
0
Extra & Other Items
0
0
0
0
0
0
0
0
0
0
Cash From Investing Activity
-2,877
-1,927
-1,787
-1,445
-1,398
-819
-246
-563
-599
-399
Net Fixed Assets
-799
-771
-1,092
125
-534
-141
-224
-376
-396
-479
Net Investments
-372
-286
-499
-171
-140
-165
-79
-136
-122
-102
Others
-1,706
-870
-196
-1,400
-724
-513
57
-51
-81
181
Cash from Financing Activity
1,919
864
-1,915
365
93
118
108
119
407
-84
Net Cash Inflow / Outflow
664
892
-424
340
-68
-55
137
-118
143
-58
Opening Cash & Equivalents
1,210
318
743
404
148
203
66
184
45
103
Closing Cash & Equivalent
1,876
1,210
320
744
461
148
203
66
184
47

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
237
199
160
124
88
64
45
40
42
33
ROA
10%
13%
14%
14%
14%
14%
4%
-2%
11%
12%
ROE
18%
23%
28%
33%
35%
37%
12%
-5%
26%
37%
ROCE
18%
23%
25%
27%
27%
27%
11%
1%
19%
22%
Fixed Asset Turnover
2.13
2.44
2.96
2.79
2.55
2.08
1.75
1.71
1.85
1.67
Receivable days
61
65
89
107
92
94
86
95
89
92
Inventory Days
122
113
101
100
89
95
106
116
104
99
Payable days
60
68
76
82
67
71
58
65
71
72
Cash Conversion Cycle
123
110
115
125
113
117
134
147
122
119
Total Debt/Equity
0.50
0.41
0.36
0.69
0.86
1.01
1.32
1.32
0.99
1.18
Interest Cover
13
43
47
12
15
6
2
0
13
11

News Update


  • Aurobindo Pharma developing range of products in US, EU markets
    25th Jun 2020, 16:15 PM

    The firm is developing eight inhalers and six nasal sprays, out of which two products have already been filed

    Read More
  • Aurobindo Pharma planning to launch 50-60 new products in US in FY21
    22nd Jun 2020, 17:03 PM

    The company has received final approval for six ANDAs (Abbreviated New Drug Application) and launched four products in the fourth quarter of last fiscal

    Read More
  • Aurobindo Pharma gets USFDA’s nod for Flucytosine Capsules
    4th May 2020, 13:05 PM

    Flucytosine Capsules are indicated for the treatment of serious infections caused by susceptible strains of Candida

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.